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Abstract
Background: The lipid fraction of cell membranes consists of polyunsaturated fatty acids (PUFAS), and chronic
alcohol use alters it, modifying its permeability, what might contribute for the dysfunctional metabolism observed
in the central nervous system of alcohol dependent patients. Therefore, the supplementation of PUFAS can be an
important adjuvant in alcoholism treatment.
Methods: This was a placebo controlled, double blind, randomized study where, 80 alcohol dependent patients,
according to DSM-IV, were allocated in four groups with 20 patient each: ‘PUFAS’, ‘Naltrexone’, ‘Naltrexone +
PUFAS’ and ‘Placebo’. Those substances were administered for 90 days and scales were applied to assess patients
craving (OCDS) and alcohol dependence severity (SADD) at baseline and after 90 days. PUFAS serum levels were
assessed before and after treatment by high performance liquid chromatography assay.
Results: Forty-three patients completed the trial. There was a significant improvement over time on drinking days,
SADD and OCDS scores in all groups (p < 0.001). The drinking days comparison between groups did not show
statistical significant difference. The same effect was observed for compulsion (OCDS) and severity of dependence
scale (SADD). The serum levels of PUFAS increased in all the supplemented groups after treatment, although not
significantly.
Conclusions: The oral supplementation of 2 g PUFAS for 3 months did not significantly differ from placebo in
reducing the amount of alcohol ingestion, or OCDS and SADD scores in a group of alcohol dependent patient.
Trial registration: NCT01211769
Background
Polyunsaturated fatty acids (PUFAS) are unsaturated
fatty acids whose carbon chain has more than one dou-
ble bond per molecule. Of those, omega-3 (n-3) and
omega-6 (n-6) are known as “essential” fatty acids, as
humans are unable to synthesize them.
The n-3 series are derived from alpha-linolenic acid
(ALA) and the n-6 series, from linoleic acid (LA). The
main ALA derivates are eicosapentaenoic acid (EPA)
and docosahexaenoic acid (DHA). Gamma linolenic acid
(GLA), dihomogamma linolenic acid (DGLA) and ara-
chidonic acid (AA) are the main LA products. GLA is
produced from LA by the enzyme delta-6-desaturase
and is further metabolized to DGLA. A small amount of
DGLA can also be converted to AA by the enzyme
delta-5-desaturase. Human conversion of ALA and LA
to their derivates is limited, and the existence of them
depends on the ingestion of certain food sources.
PUFAS are key components to the brain and count up
to 15-20% of its dry mass [1]. Other relevant roles of
PUFAS are the influence over fluidity of neuronal mem-
branes and acting as second messengers in neurotrans-
mitter systems [2]. According to Naliwaiko, et al. [3],
changes in cell membrane fatty acid composition occurs
in the central nervous system (CNS) depending on
PUFAS dietary intake [4,5]. Therefore it has been postu-
lated that adequate supplementation of omega-3 and
omega-6 would have beneficial effects on brain
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been established [6].
Omega-3 fatty acids have been associated with several
benefits. This is particularlyt r u ef o rt w oe s s e n t i a lf a t t y
acids of the omega-3 family; docosahexaenoic acid
(DHA) and eicosapentaenoic acid (EPA). As an example,
it has been used as an adjuvant treatment of systemic
hypertension, Crohn’s disease, rheumatoid arthritis, age-
related macular disease and asthma with favorable out-
comes. There are also reports of effectiveness in redu-
cing risk of primary cardiac and promising data on the
prevention of breast and lung cancer [7,8].
In psychiatry, the strongest evidence of the beneficial
effects of omega-3 is in mood disorders. A meta-analysis
involving patients with major depressive disorder and
bipolar disorder provided evidence that 1 to 2 grams
daily of omega-3 PUFA supplementation can reduce
symptoms of depression [9]. Furthermore, it has been
suggested that supplementation with eicosapentaenoic
acid may be more beneficial than that of docosahexae-
noic acid in these disorders [10-12]. Although several
factors do not allow definitive conclusions about what
kind of omega-3 would bring better results. Other stu-
dies also support the action of PUFAS in reducing the
number of relapses of cocaine addicts, minimizing the
aggressiveness [13,14], improving bipolar disorders [15]
and borderline personality disorder symptoms [16,17].
In 1987, Glen et al. summarized alcohol effects in
PUFAS metabolism. He stated that ethanol consumption
leads to an increase in the ratio of linoleic to arachido-
nic acid in the phospholipids of tissues. Some of the
main contributors for this PUFAS altered ratio would be
a reduced intake, absorption, and alteration in fatty acid
metabolism [18]. Alcohol also inhibits ∂-6 and ∂-5-desa-
turases, enzymes associated with the conversion of lino-
leic acid to gamma linolenic (GLA), and dihomogamma
linolenic acids to arachidonic acid [19]. Moreover alco-
hol has a direct effect on cell membranes composition.
A relative increase in n-6 PUFAS in the membranes
increases the fluidity resulting in cell damage. Interest-
ingly, it has been reported that this pathological effect
could be reduced, at least partially by fatty acid supple-
mentation, especially n-3 PUFAS [18].
Previous studies have evaluated the role of PUFAS in
alcoholism. They are linked to the action of neuro-
transmitters [20], liver damage produced by alcohol
[21,22], their effects on tolerance [23] and even as
attenuators of the negative effects of chronic alcohol
use [24]. Treatment with omega-3 looks promising,
but few studies have been published so far. Further
studies are needed to identify individuals likely to be
benefited by this type of treatment, assess the durabil-
ity of these effects and to determine dosage and treat-
ment time recommended [25].
There is no literature to date, associating PUFAS as a
potential treatment to prevent compulsion for alcohol.
This association seems plausible, since the lipid fraction
of cell membranes consists of PUFAS, and chronic alco-
hol use alter the absorption of these acids, modifying its
permeability. The aim of this study was to investigate
the effects of PUFAS in alcohol-dependent patients, and
to evaluate the possible reduction in craving for alcohol.
Methods
The present study is a placebo controlled, double blind,
randomized trial. It was approved by the Institutional
Board Review (IRB) at Federal University of Sao Paulo -
UNIFESP (CEP 0185/06).
Patients Selection
The research was announced in the media (radio and
Metro newspaper) and Federal University of Sao Paulo
internal network, and followed by an initial selection of
volunteers (initial telephone contact). For this initial
screening, the inclusion criteria were: male subjects,
aged between 30 and 50, dependent of alcohol according
to DSM-IV [26], with no history of known clinical dis-
ease, Axis I psychiatric comorbidities, or other substance
misuse in the past month (except for tobacco).
After the screening, patients were invited to a clinical
interview. The interview included medical and psychia-
tric history and physical examination. Following the
interview, volunteers underwent laboratorial workup
which consisted of: uric acid, albumin, amylase, bilirubin
and fractions, calcium, phosphorus, total cholesterol,
HDL, LDL, creatinine, alkaline phosphatase, fasting glu-
cose, complete blood count, lipid profile T3, T4 and
TSH, SGOT, SGPT, triglycerides, urea, urinalysis,
VDRL, Serologic tests for (Hepatitis A, Hepatitis B,
Hepatitis C, Chagas disease and Elisa for HIV), Screen-
ing for drugs of abuse (cocaine, THC, methampheta-
mine, barbiturates, phencyclidine, amphetamine,
morphine and benzodiazepines).
The volunteers eligible to participate in the study
received written information pertinent to the research,
including the safety aspects and risks of the adminis-
tered substances, and signed the informed consent.
Treatment arms
After selection patients were randomized into four
groups: ‘Placebo’, ‘Naltrexone’, ‘PUFAS’ and ‘Naltrexone
+P U F A S ’. The composition of PUFAS capsules was of
1gBorago officinalis oil (rich in omega 6) and another
of 1 g of fish oil (rich in omega 3). The capsules were
provided from Herbarium Laboratório Botânico
(Colombo, PR, Brazil) and contained respectively 120
mg of GLA and 400 mg EPA + DHA, which corre-
sponds to a ratio of approximately (3, 5: 1) between
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gested benefic [6]. The fish oil capsule composition was
160 mg of EPA and 240 mg of DHA. Capsules of liquid
paraffin composed the placebo version of PUFAS. Cris-
tália Produtos Químicos Farmacêuticos LTDA (Itapira,
SP, Brazil) provided Naltrexone 50 mg and also identical
placebo-Naltrexone pills.
The medications were administered daily, after an
initial period of seven days of detoxification. Patients
were then followed monthly for 90 days, allowing obser-
vation of possible side effects that might implicate in
volunteers exclusion from the study. Patient returned the
empty bottles of medication on each visit (end of first,
second and third month), as well as a calendar with the
marked days in which they took the medication.
Follow-up measurements
The serum level of PUFAS (EPA, DHA, AA and Linoleic
acid) was dosed at the baseline and last day of follow-
up. The quantification protocol of PUFAS dosage was
conducted as described by Naliwako et al [3] using the
high performance liquid chromatography technique
(HPLC). Briefly, total lipids were extracted from plasma,
using chloroform-methanol (2:1 vol/vol). Fatty acids
were derivatized with 4-bromomethyl-7-coumarin and
then separated on a Shimadzu LC-10A high perfor-
mance liquid chromatograph using an octa- decylsilica
column (25 cm £ 4:6 mm i.d.; particle size 5 mm). Fatty
acids were resolved isocratically using a mobile phase of
acetonitrile-water (gradient from 77:23 to 90:10 vol/vol)
at a flow rate of 1 ml/min. Fatty acid derivatives were
detected by fluorescence (325-nm excitation; 395-nm
emission).
During the study, two scales were applied to assess
patients craving and alcohol dependence severity, at the
baseline visit and three months after the initiation of
treatment. The SADD questionnaire (Short Alcohol
Dependence Data), a self-completion questionnaire
designed to evaluate the presence and the degree of
severity of alcohol dependence, adapted and validated
f o ru s ei nB r a z i lb yJ o r g e&M a s u r[ 2 7 ] ;a n dt h eO C D S
Scale (Obsessive-Compulsive Drinking Scale), also a self
rating scale, looking at obsessive thinking and compul-
sive desire to use alcohol.
Statistical Analysis
Continuous variables were tested by means of tests of
normality, to verify pre-requisites for the implementa-
tion of parametric tests. Shapiro Wilk tests were per-
formed for normality and variables without normal
distribution were tested with non-parametric tests. To
assess whether in baseline, the groups had similar
results in relation to the “drinking days” and measures
of the scales SADD and OCDS, we used the non-
parametric test Kruskal-Wallis, which showed no statis-
tical difference between groups. To compare if there
were differences on Drinking Days or SADD and OCDS
scales between the groups and over the time of follow-
up, repeated measures ANOVA were performed.
To assess if there was any difference between the ana-
lyzed groups, scores of SADD and OCDS were ranked,
and chi-square tests were performed. SADD question-
naire was ranked in “low dependence” (1 - 9), “medium
dependence” (10 - 19) and “high dependence” (20 - 45),
as previously reported by Raistrick et al [28]. The
OCDS scores were separated in “insignificant” (0 - 5),
“low craving” (6 - 14), “medium craving” (15 - 25) and
“severe craving” (26 and above), as in previous publica-
tion [29].
The statistical software Statistica for Windows (ver-
sion 9.0) was used to perform the above-mentioned
analysis.
Results
A total of 80 patients, 20 per group were enrolled. The
groups did not differ at the baseline from demographic
characteristics, such as: marital status, educational level
or employment status. At the end of three moth follow-
up period, 43 patients were still in the study: PUFAS (n
= 12), naltrexone (n = 11), naltrexone + PUFAS (n = 9)
and Placebo (n = 11). Thirty-seven patients were
excluded: 30 due to incomplete follow-up, 2 for clinical
complications and 5 were referred to inpatient unit care.
All groups improved at the end of 3 months. The
repeated measures ANOVA showed significant effect of
time in relation to “drinking days”, SADD and OCDS in
all groups (p < 0.001). At the beginning of the study,
patient referred to have drunk in 20.49 (± 9.78) of the
30 days previous to the scheduled appointment. In the
final visit it was reduced to 7.95 days (± 10.80).
As for SADD questionnaire, the baseline score was
33.17 (± 10.39) and the final measure was 10.86 (±
13.49). Dependence severity was ranked as: severe
dependents 90% of the patients (n = 72), moderate
dependents 9% (n = 7) and only one patient was consid-
ered to have a low severity. Remarkably, in the final
appointment, of the 43 patients that remained in the
study, 23% were still severe dependents (n = 10), 14%
had a moderate classification (n = 6), 28% were ranked
as low dependents (n = 12) and 35% did not point at all
in the questionnaire (n = 15). A Chi-square test per-
formed did not show any difference between the groups
according to the SADD analysis.
Regarding the OCDS scale, in the baseline assessment,
patient had a mean score of 40.81 (± 13.07) and 14, 67
(± 16.33) in the final visit. When ranked, 72 of the 80
patients were considered to have a strong craving, 5
patient a moderate and 3 were classified as low in the
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43 patients had their craving ranked respectively as
strong 21% (n = 9), moderate 16% (n = 7), low 19% (n =
8) and insignificant 64% (n = 19). Again, the Chi-square
test was performed, and no difference was observed
between the studied groups.
There was no statistical significant difference in the
drop-out rate between the studied groups (PUFAS, Pla-
cebo, Naltrexone and Naltrexone + PUFAS). There was
a statistical significant difference of treatment comple-
tion in “drinking days” (p = 0.03). The mean “drinking
days” in the last month of patient that completed the
trial was 18.46 (± 1.46), while in the “drop-out” group, it
was of 23.08 (± 1.57). There was no statistical difference
of SADD (p = 0.50) or OCDS (p = 0.69) scores in the
baseline moment, between patients who dropped out.
The accumulated data suggest that OCDS scores
increases in relationship to the severity of the alcohol
dependence syndrome [30]. In our study it was observed
a highly significant correlation between the two instru-
ments (+ 0.94). The initial and final mean values
o b t a i n e df o rd r i n k i n gd a y s ,S A D Da n dO C D Si ne a c h
group are demonstrated in Figure 1.
Regarding the laboratory work-up, there was no differ-
ence between the groups or over time for total choles-
terol, HDL, LDL, alkaline phosphate, SGOT, SGPT,
GGT and all other general exams performed. As for
PUFAS dosage, the repeated measures ANOVA did not
show a significant difference between groups and from
the baseline to final visit dosages for EPA, DHA, AA or
Linoleic acid. Figure 2 illustrates the results in each
group.
No patients had any serious adverse event. Some of
them (16, 21%, n = 80) complained of minor gastroin-
testinal disturbance.
Discussion
In this study, the daily administration of PUFAS and
Naltrexone, for a period of 3 months did not signifi-
cantly differ from placebo in reducing the amount of
alcohol ingestion, or OCDS and SADD scores in a
group of severe alcohol dependent patient.
Overall all the four groups reduced significantly the
amount of alcohol ingestion, dependence severity and
compulsion for alcohol, when compared the baseline
and the last visit values. This could be possibly
explained by the severity of patient’sd e p e n d e n c ei nt h e
present trial. As patients had extremely severe depen-
dence, high scores on SADD scale (mean SADD 33.55;
± 10.09), they might have benefited from the simple fact
of been followed for a three-month period, received
medical consultation, as well as “pharmacological treat-
ment” (studied drugs or placebo). This could be an
explanation of why the placebo group had similar
improvement as the other treatment groups.
Several clinical studies have investigated the time and
dose-dependent incorporation and successive washout
of n-3 PUFAS in different biological tissues following
dietary supplementation [31]. The evidence to date indi-
cates that modest amounts of n-3 PUFAS can rapidly
change the composition of fatty acids in blood cell
membranes. A low-dose approach (1 g/day) appears jus-
tified by the concordance of biological and clinical find-
ings. The International Society for the Study of Fatty
Acids and Lipids (ISSFAL) for cardiovascular health,
recommends a daily intake of EPA and DHA of 500 mg.
Hibbeln et al. have proposed that the amount which
would protect against major psychiatric diseases should
be as high as 3.5 g per day [32]. The present trial sup-
plemented 400 mg of EPA+DHA and 120 mg of GLA,
which could not be an optimal dose for patients that are
Figure 1 Repeated Measures ANOVA of “Drinking Days”, OCDS scale and SADD questionnaire. (A) This graph represents the repeated
measures ANOVA comparing the mean values of “drinking days” from baseline over time between the studied groups. (B) This graph represents
the repeated measures ANOVA comparing the mean values of OCDS scale from baseline over time between the studied groups. (C) This graph
represents the repeated measures ANOVA comparing the mean values of SADD questionnaire from baseline over time between the studied
groups. * p values ≤ 0.001.
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dependents. Therefore, it is possible that the amount of
PUFAS administrated was not high enough to benefit
the studied population, what could justify the lack of an
expected positive effect.
It is important to remark that even though no statis-
tical differences were found between the groups, all
PUFAS measurements increased in the groups to
whom it was supplemented (Figure 2). Apparently, this
increase was less intense in the group that also
received naltrexone. Also, in the group that was given
naltrexone alone, EPA, DHA and Linoleic acid dosages
decreased. This effect could be related to the hipoli-
paemic effect cased by naltrexone, previously reported
in both animal and human studies. Naltrexone pre-
vented the stress-induced increase in total and LDL
cholesterol in rats during stress caused by immobiliza-
tion and a decrease in HDL-C levels [33]. Also, in
patients treated with naltrexone, there was a significant
decrease in total cholesterol (TC) concentration after
16 weeks of pharmacotherapy. Patients treated with
naltrexone had lower mean TC (P < 0.03) and LDL-C
(P < 0.01) than patients of the remaining pharma-
cotherapy groups [33]. In our study, even with only 12
weeks of treatment, a trend in naltrexone effects over
P U F A S ,T Ca n dL D L - Cc o u l db eo b s e r v e d( F i g u r e s2
and 3).
It would have been interesting to obtain a dietary daily
report of PUFAS ingestion by those patients. As they
were treated on an outpatient basis and many kept
drinking during the study, this could have helped to dif-
ferentiate an inadequate diet from the deleterious effect
of alcohol, in incorporating PUFAS to the cell mem-
brane [34].
Another point to consider is the interaction between
n-3 and n-6 series. Most of the studied conducted until
now, administered only one PUFAS series, usually n-3.
The patients enrolled in our study could be extremely
depleted in the n-3 series, even more than from n-6 ser-
ies. If that was true, they could benefit more from n-3
administration as monotherapy. It would be interesting,
in future trials, to assess which would be a reference
mean rate of PUFAS serum dosages in alcohol depen-
dent patients, what would help to define which PUFAS
Figure 2 Repeated Measures ANOVA of PUFAS serum measures. (A) This graph represents the repeated measures ANOVA comparing the
mean values of the percentage of EPA obtained from plasma total lipids, from baseline over time between the studied groups. (B) This graph
represents the repeated measures ANOVA comparing the mean values of the percentage of DHA obtained from plasma total lipids, from
baseline over time between the studied groups. (C) This graph represents the repeated measures ANOVA comparing the mean values of the
percentage of AA obtained from plasma total lipids, from baseline over time between the studied groups. (D) This graph represents the
repeated measures ANOVA comparing the mean values of the percentage of Linoleic Acid obtained from plasma total lipids, from baseline over
time between the studied groups.
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outcomes.
An important consideration to be made is that, even
though there was an increase on PUFAS serum dosages
on the supplemented groups, the lack of adherence to
the medications administered is still a concern. Despite
being given calendar with dates and times (to check indi-
vidually) and guided of its correct usage, some patients
reported having completed the calendar at the day of
consultation, because they forgot to check it in advance.
Comparisons also might have failed to reach statistical
significance because the relatively small number of
patients failed to lend enough power to the statistical
analyses. As in other clinical trials for substance depen-
dence, specially in an outpatient basis, most of the
patients who start treatment do not accomplish to com-
plete it [35]. Subsequent studies with more participants
are needed to assess the possible benefit of the adminis-
tration of polyunsaturated fatty acids to alcohol-depen-
dent patients, either as monotherapy or in combination
with naltrexone.
Our interpretation of the data should be taken in the
context of our study’s possible limitations. It should be
pointed out that, to date, there is no data on the efficacy
of PUFAS in alcohol dependence treatment. There are
some studies aiming substance abuse population, but
most of them have patient in use of more than one sub-
stance or medication such as methadone and antide-
pressants [6,36,37]. We aimed a very specific population
of severe dependent patient that had no clinical comor-
bidities and in no use of other drugs of abuse as
cocaine, heroin, cannabis or even benzodiazepines and
other prescribed psychotropic medications.
Study Limitations
Studies aiming substance abuse or dependence and
PUFAS supplementation are very limited and to our
knowledge, there is no combination proven to have
positive effects on alcohol consumption or alcohol
dependence severity.
In this study patient were given, 160 mg of EPA, 240
mg of DHA and 120 mg of GLA. The administration of
both omega-3 and omega-6 aimed an increase of poly-
unsaturated and consequent decrease of saturated fatty
acids membrane content. A low dosage was chosen
because previous studies had demonstrated positive
effects in other population. Another major concern in
an outpatient trial is compliance, as patient would have
to take a greater number of capsules in order to enlarge
PUFAS supplementation.
EPA, DHA and GLA are major PUFAS components of
cell membrane and have shown several benefits to
human health. EPA and DHA are the two types of
omega-3 fatty acids that serve as important precursors
for lipid-derived modulators of cell signaling, gene
expression and inflammatory processes [38]. GLA, a n-6
fatty acid have gained importance in the last four dec-
ades for its anti-inflammatory and anti-cancer actions.
GLA and its metabolites also affect expression of various
genes and play a significant role in immune functions
and apoptosis [39]. Omega-6 fatty acids possibly also
play a role as second messengers in the process of signal
transduction across cell membranes [40].
Several clinical trials have supplemented PUFAS to the
most diverse population. There is a wide range of
dosage administered and combination of fatty acids.
Some examples are a 6-month trial supplementing 80
mg EPA and 120 mg DHA that significantly protected
an elderly population from a rise in serum triglycerides
[41]; 80 mg AA daily for 3 weeks which increased the
composition of AA, but did not decrease the composi-
tion of n-3 in young woman [42]; 324 mg EPA + 216
m gD H A+4 8 0m gL Aa n d2 5 8m gG L Ad a i l y
improved pulmonary status, inflammatory and
Figure 3 Repeated Measures ANOVA of LDL and total cholesterol. (A) This graph represents the repeated measures ANOVA comparing the
mean values of Total cholesterol from baseline over time between the studied groups. (B) This graph represents the repeated measures ANOVA
comparing the mean values of LDL cholesterol from baseline over time between the studied groups.
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[43]; and supplementation with only 200 mg DHA for 2
weeks induced an antioxidant effect, not achieved with
1600 mg [44].
There was an important drop-out from the start of the
study until its completion 3 months later (from 80
patients to 43). A drop-out rate was expected, as the
study was designed in an outpatient basis, but this loss
overcame our expectations. Perhaps if they had addi-
tional visits, or associated psychotherapy, we could have
had better results. As in majority of trials, patient who
do not complete, tend to be the most severe ones. How-
ever, there was no statistical significant difference in the
drop-out rate between the studied groups (PUFAS, Pla-
cebo, Naltrexone and Naltrexone + PUFAS) as pre-
viously discussed.
Another curious question is why there were no signifi-
cant differences from baseline to final visit in EPA,
DHA, AA and LA. It is possible that the given dosages
were small and as the difference in PUFAS blood dosage
was not statistical significant. We also have to consider
that patient might not have taken their medication
properly. They filled a calendar, as well as returned their
empty medication container, but this does not necessary
mean that they took the capsules as recommended. It is
also important to take in account a possible hypolipae-
mic effect of Naltrexone as previously mentioned in the
text.
Conclusions
The administration of 120 mg of GLA and 400 mg EPA
+ DHA (160 mg EPA and 240 mg DHA), for 3 months
did not significantly differ from placebo in reducing the
amount of alcohol ingestion, or OCDS and SADD
scores in a group of alcohol dependent patient. Subse-
quent studies with more participants are needed to
assess the possible benefit of the administration of poly-
unsaturated fatty acids to alcohol-dependent patients,
either as monotherapy or in combination with
naltrexone.
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